ϩ , CD8 ϩ T-cell line, G2, was derived from the peripheral blood of a seropositive, PCR-positive, HTLV-IIB infected Guahibo Indian from Venezuela. The cell line is productively infected with HTLV-IIB. The entire HTLV-II G2 proviral DNA was sequenced via PCR using overlapping HTLV-II primer pairs. Phylogenetic analyses indicate that HTLV-II G2 is the most divergent HTLV-IIB strain identified to date. Characterization of its deduced proteins and its relationship to other members of the PTLV/BLV genus of retroviruses are discussed.
The human T-cell lymphoma/leukemia viruses I and II (HTLV-I and HTLV-II) belong to a group of complex oncogenic retroviruses (Kalyanaraman et al., 1982; Poiesz et al., 1980) . HTLV-I is associated with a variety of clinical disorders, including T-cell lymphomas and leukemias, neurodegenerative disease, polymyositis, arthritis, and uveitis (Bhagavati et al., 1988; Mochizuki et al., 1992; Poiesz et al., 1980; Sherman et al., 1995) . HTLV-II has been increasingly associated with rare lymphocytic neoplasms and cases of neurodegenerative disease (Harrington et al., 1993; Hjelle et al., 1992; Kalyanaraman et al., 1982; Loughran et al., 1992; Lowis et al., in press; Rosenblatt et al., 1988) .
HTLV-I and HTLV-II are Ϸ60% homologous at the genetic level (Seiki et al., 1983; Shimotohno et al., 1985) . Together with a variety of related retroviruses detected in nonhuman primates, they share a common ancestor with bovine leukemia virus (BLV) with which they form a genus (Dube et al., 1997) . The strains of this genus found in nonhuman primate hosts are often referred to as simian T-cell lymphoma leukemia viruses (STLV). However, because of many incidences of cross-species transmission, the HTLV and STLV do not segregate phylogenetically according to host species of origin but rather according to geography. Hence, it is easier to refer to HTLV and STLV collectively as the primate T-cell lymphoma/ leukemia viruses (PTLV) and discuss their phylogenetic subgroupings as PTLV-I, PTLV-II, etc. (Dube et al., 1997) .
There are two major subtypes of HTLV-II, A and B, which are about 94% homologous to each other Hall et al., 1992) . Most North Americans infected with HTLV-II, including intravenous drug users in whom the virus is endemic, are infected with subtype A, whereas most Paleo-Amerindians from Florida, Central America, and South America are infected with subtype B Ferrer et al., 1996; Hall et al., 1992; Leon-Ponte et al., 1998; Neel et al., 1994) . Interestingly, the Indians of the Amazon river basin are infected with a variant of subtype A (Ishak et al., 1995; Switzer et al., 1996) and HTLV-II is endemic among some African pygmy groups (Goubau et al., 1992) .
Recently, we have shown that HTLV-II is endemic among some, but not all, Venezuelan Amerindians (Echeverria de Perez et al., 1992 Perez et al., , 1993 Leon-Ponte et al., 1996 . A particular isolate, HTLV-IIB G2, obtained from a Guahibo Indian, was found to be the most divergent HTLV-IIB strain identified to date (Leon-Ponte et al., 1998) . We decided to fully sequence this unique isolate in order to compare it phylogenetically to other members of its genus and to have a structural blueprint for correlation with observed in vitro and in vivo functional phenomena.
RESULTS

Cell line production
After 4 weeks of culture, peripheral blood mononuclear cells (PBMCs) from G2 developed the features of an HTLV-II infected cell line with syncitial formation characterized by large bi-and multinucleated cells and some "hairy" cytoplasmic projections (Popovic et al., 1983) . Cells proliferated rapidly with a doubling time of less than 24 h and were split each third to fourth day. HTLV p19 antigen was detected in the culture supernatants of the G2 cell line at week 4 (Fig. 1) . HTLV antigens were detected in the G2 cultured cells by indirect immunofluorescence using polyvalent human anti-HTLV-II antibodies after 2 months in culture; 60 to 85% of the cells were fluorescent, showing the typical pattern of HTLV antigens when incubated with the HTLV-II-positive sera. Controls were as expected, with no fluorescence for H9 and strong positivity for both MT2 and clone 19. The cell line is still dependent on exogenous IL-2.
Cell line phenotypic and molecular analyses
After 3 months in culture, cell surface phenotype analyses showed that the G2 cell line was CD3
ϩ , CD25 ϩ , and CD45RO ϩ and also expressed high levels of HLA-DR antigen. This phenotypic analysis demonstrated that the cell line consisted of mature, activated, suppressor/cytotoxic T-cells of the killer effector type. Polymerase chain reaction (PCR) analysis indicated that at 3 months of culture the cell line was polyclonal with respect to T-cell receptor ␤-gene rearrangements (data not shown).
Viral nucleic acid studies
Serial endpoint dilutions indicate that there is at least one copy of HTLV-II per cell in the G2 culture. PCR amplification and Southern blot detection were successful for each of the primer pair/probe groups shown in Fig.  2 . Some primer pair/probe systems not listed were not successful, usually because of G2-specific mutations (data not shown). PCR using the primer pair HTII 916-934 ϩ /HTII 1375-1394 Ϫ in the 5Ј end of the HTLV-II gag gene (Fig. 2 ) resulted in two distinct amplified products; both were sequenced (Fig. 3) . The larger (minority) product represents the wild-type HTLV-II sequence, while the smaller (majority) product contains a 66-base deletion in the 5Ј end of the HTLV-II G2 gag gene. We will refer to these deleted sequences as HTLV-II G2 del. The deletion would not be expected to produce a frameshift and would not alter the protease cleavage site involved in processing the Gag polyprotein. It would result in a smaller p19 gag protein. The complete sequence of HTLV-II G2 was obtained from these overlapping amplified products (GenBank Accession No. AF074965). Enough fresh PBMC DNA was available to validate that most of the HTLV-II sequences obtained from G2 cell line DNA were also present in vivo; unfortunately, none was left to ascertain whether HTLV-II G2 del was present in vivo or was an artifact of culture. However, when fresh PBMCs from three HTLV-II infected individuals (two subtype A and one subtype B) and cell culture DNA from G2 and the HTLV-IIA infected cell line MoT were amplified, all had both the wild-type and the deleted sequences (data not shown). Interestingly, in the two cell cultures, the deleted sequence was the dominant species present, while in the in vivo specimens, the opposite was the case (data not shown).
Comparative analyses of HTLV-II G2 indicate that it belongs to the HTLV-IIB subtype (Figs. 3, 4, and 5) . It is 94.8, 98.4, and 62.6% homologous to the prototypical HTLV-IIA MoT, HTLV-IIB NRA, and HTLV-I ATK strains, respectively. Its LTR sequences (Fig. 4) are intact, containing the usual three 21-bp repeat enhancer sequences 5Ј to the TATA box promoter typical of all HTLV. These regions interact with cellular CREB/ATF proteins complexed with the viral Tax protein to upregulate viral transcription. HTLV-II G2 genomic RNA would be predicted to have a typical 3Ј poly(A) signal, a Rex response element, and a 5Ј proline tRNA primer binding site. The LTR proviral DNA contains 10 potential methylation sites (one more than found in prototype strains) 5Ј to the TATA box promoter.
As stated above, the deduced amino sequences for the HTLV-II G2 p19 gag protein show both a wild-type and a mutant form, with the mutant being 22 amino acids shorter on its carboxy-terminus but still retaining its myristylation site (Fig. 3 ). Whether this mutant protein is produced in vitro or in vivo and whether it is functional are currently unknown. Of note, the HTLV-II G2 p19 protein is more divergent from that of the HTLV-IIB NRA strain than it is from the HTLV-IIA Mot strain (Fig. 3) . It is 61.8% homologous to its HTLV-I counterpart (data not shown). The deduced p24 gag, p15 gag, and protease amino acids of HTLV-II G2 again are typical of an HTLV-IIB sequence and are 86.4, 69.8, and 53.9% homologous to those of HTLV-I (Fig. 3 , and data not shown). Both the HTLV-I and the HTLV-II proteases contain aspartyl-specific recognition motifs. The cognate proteins of the pol gene of HTLV-II G2, namely those that encode for RNase H, reverse transcriptase, and integrase functions, show that they are typical of an HTLV-IIB strain and are smaller than and 60.6% homologous to those of HTLV-I (Fig. 3 , and data not shown).
The amino acid sequences of the HTLV-II G2 gp46 and gp21 envelope proteins are also characteristic of an HTLV-IIB isolate with reasonable, but not complete, conservation of the immunodominant HTLV-II gp46-specific epitope GH2K15 (Fig. 3 ) utilized in HTLV-I/II discriminatory and confirmatory antibody detection assays and also complete conservation of the HTLV-II gp46 neutralizing domain (Fig. 3) (Lipka et al., 1992; Sherman et al., 1993) . Also preserved are the GD21 and BA21 epitopes of the HTLV gp21 env transmembrane protein (Fig. 3) . Seroreactivity against an HTLV-I GD21 peptide among infected humans and animals is highly sensitive and specific for infection with a member of the BLV/PTLV genus, whereas reactivity to an HTLV-I BA21 peptide is less frequent in truly infected humans and is often positive in uninfected individuals (Hadlock et al., 1995; . The HTLV-I GD21 peptide is now included in highly sensitive and specific Western blot assays for HTLV antibodies. The HTLV-II GD21 epitope is 85% homologous to its HTLV-I counterpart (data not shown). Taken together the HTLV-II G2 env proteins are 63.5% homologous to their HTLV-I counterparts.
Characterization of the deduced HTLV-II G2 regulatory proteins shows that the Tax transactivator protein is highly conserved and of the characteristic larger size of most HTLV-IIB, HTLV-I, and HTLV-IIA Kayapo strains relative to other HTLV-IIA strains (Fig. 3) . HTLV-II G2 Tax is 80.0% homologous to that of HTLV-I (data not shown). Similarly, the Rex protein, which regulates viral RNA splicing, is also highly conserved among the HTLV-II strains (Fig. 3) . HTLV-II G2 Rex is 62.7% homologous to the HTLV-I Rex (data not shown). Several other proteins, p10 XI , p28 XII , and p22 XIII /20 XIII , and p11 XV , encoded by the regulatory genes of the HTLV have been identified (Ciminale et al., 1995) . Their functions remain unknown, but there are only minor differences in G2 relative to other HTLV-II strains (Fig. 3) . The HTLV-II p10 XI , p28 XII , and p22 XIII /p20 XIII peptides are 43.4, 77.6, and 60.0% homologous to their counterparts in HTLV-I (data not shown). There is no p11 XV equivalent expressed in HTLV-I. Phylogenetic comparisons of the HTLV-II G2 pol DNA sequence to other published BLV and PTLV sequences indicate that G2 belongs to the HTLV-IIB subtype (Fig. 5) . The data support the interpretation that the BLV and (Shimotohno et al., 1985) . The primers overlapping oligonucleotide pairs utilized for PCR are shown below the proviral DNA. Their inclusive base numbers are also derived from the HTLV-IIA isolate MoT. By convention, we refer to each primer as HTII for HTLV-II and then the list inclusive base numbers and the polarity of the DNA strand. For example, the first primer is HTII 26-47 ϩ .
FIG. 3.
Amino acid sequence of the various proteins of HTLV-II G2 compared to those of the prototypical HTLV-IIA isolate MoT and the prototypical HTLV-IIB isolate NRA. The bullet shows areas of homology while the amino acid substitutions are as indicated. The ends of the various proteins are indicated by the a symbol. The wild-type p19 sequence is shown but the deleted region is indicated by a line above the sequence. The interesting immunoreactive regions of the gp46 and gp21 env proteins discussed in the text are also indicated.
PTLV evolved from a common ancestor. Shortly after the PTLV-I separated from the PTLV-II, a branch represented by PTLV-L (from an Eritrean baboon) (Van Brussel et al., 1997) diverged from STLV-II (from an African pygmy chimp) (Digilio et al., 1997) and from the branch we currently refer to as HTLV-II. Much later, the PTLV-I branched into African and Asian/Austronesian subgroups and the HTLV-II into the A and B subgroups.
DISCUSSION
HTLV-II is a member of a genus of pathogenic retroviruses that cause a variety of malignant and autoimmune diseases in cattle, humans, and nonhuman primates. To date, prototypic HTLV-II has been found only in humans, while the PTLV-I (HTLV-I and STLV-I) are found in both humans and nonhuman primates, with evidence of multiple cross-species transmissions over the past thousands of years. All worldwide HTLV-II sequences described to date have high homology to those strains identified in the New World, including those from very isolated Paleo-Amerindian groups, like the HTLV-II G2 isolate described herein. This suggests that they represent a relatively recent dissemination from the Western Hemisphere. Presumably, the introduction of HTLV-II into
FIG. 3-Continued
humans came from an ancient transmission of a virus with a common ancestor to both PTLV-L and STLV-II as the Paleo-Amerindians migrated into the New World. To these authors, the distance in separation between HTLV-II and PTLV-L is so great that it might make more taxonomic sense to refer to the PTLV-L strain as belonging to "PTLV-III." To date, no humans have been shown to be infected with a retrovirus with high homology to either the PTLV-L or the STLV-II strains. Obviously, this is an extremely interesting area for further research, as is the hypothesis that there await to be identified modern examples of side branches to the relatively uncomplicated BLV arm of the PTLV/BLV evolutionary tree (Fig. 5) .
BLV and the PTLV-I are clearly pathogenic to their
hosts, causing disease in approximately 4% of infected individuals (Poiesz, 1995) . Perinatal infection with HTLV-I is associated with a 10% incidence of CD4 ϩ leukemia/ lymphoma over the hosts' lifetimes (Kondo et al., 1985; Murphy et al., 1989) . Currently, it is not clear whether the STLV-II or PTLV-L strains are pathogenic in their respective hosts. HTLV-II is known to be associated with clonal expansions of human T-cells in vivo, with infection being skewed, but not restricted, to CD8 ϩ lymphocytes (Cimarelli et al., 1996; Ijichi et al., 1992; Lal et al., 1995; . Also, HTLV-II has been associated with rare T-cell malignancies, including large granular lymphocyte (LGL) leukemias, which, when typed, have usually been shown to be of the CD8 ϩ phenotype (Kalyanaraman et al., 1982; Loughran et al., 1992; Rosenblatt et al., 1988; Zucker-Franklin et al., 1992) . In some but not all of these cases, HTLV-II proviral DNA has been shown to be monoclonally integrated into the host DNA (Kalyanaraman et al., 1982; Rosenblatt et al., 1988) . The fresh PBMCs of donor G2 showed no evidence for CD8 ϩ lymphocytosis but were never evaluated for LGL lymphocytes or the presence of T-cell clonal expansion. The G2 cell line is a polyclonal CD8 ϩ culture; hence, it is impossible to speculate whether donor G2 had any evidence of leukemia.
As is the case with HTLV-I, defective copies of HTLV-II have been identified in vivo, but the clinical impact of this finding is unknown . The finding of a deleted HTLV-II p19 mutant in the G2 cell line is not unique. Others have also found the same deletion, but not the wild-type sequence, in two HTLV-IIB-positive cell lines (Takahashi et al., 1993) . Our data herein and the published HTLV-IIB NRA sequence indicate that HTLV-IIB strains can contain the full-length wild-type sequence. However, serology studies indicate that the linear epitope contained in the deleted 22 amino acids may be expressed in HTLV-IIA infected individuals but not in HTLV-IIB infected individuals (Takahashi et al., 1993) . Our data would suggest that the wild-type sequence may be the predominant species in vivo, with the deleted sequence dominating in vitro. Whether this is truly the case, and why this should be so, will require further investigation. Current serologic assays for HTLV-I or HTLV-II infection are based primarily on HTLV-I antigen preparation. Only recently have HTLV-II antigens been included in the assays. HTLV-II G2 is only the fourth fully sequenced HTLV-II strain. As shown herein, this sequence further extends our knowledge of the breadth of HTLV-II amino acid diversity. Comparative PCR and serologic assays with defined HTLV peptides in well-characterized HTLV infected populations will be required to fully evaluate the The G2 cell line, the HTLV-II G2 isolate, and the Guahibo Indian group offer ideal opportunities to study the biology of HTLV-II in humans. G2 represents a rare cell line that should be an invaluable tool for understanding the impact of HTLV-II expression on the biology of CD8 ϩ T-lymphocytes. Subclones of the cell line, as well as infectious clones of the wild-type and mutant HTLV-II G2 strains, could be produced and examined for differences in their cellular and viral biology. Finally, continued clinical monitoring of the Guahibo and other Paleo-Amerindian groups should allow for further clarification of the pathogenesis of HTLV-II and evaluation of the performance of various HTLV detection techniques.
MATERIALS AND METHODS
Cell culture
In December 1995, fresh PBMCs were obtained from an HTLV-II seropositive, PCR-positive Venezuelan Guahibo Indian identified as G2 (Leon-Ponte et al., 1998) . Ten million cells were cryopreserved for further DNA extraction and sequencing analysis. At the time the sample was obtained, the donor had 5.9 ϫ 10 3 white blood cells per microliter of peripheral blood with a differential of 36% lymphocytes, 10% monocytes, 48% neutrophils, 6% eosinophils, and 0% basophils. No assessment of LGL numbers was made at that time. Absolute lymphocyte subset counts were as follows:
ϩ (765/l); and CD3 ϩ /CD8 ϩ (510/l). This last value was no different than the median CD3 ϩ /CD8 ϩ count (504/l) of non-HTLV-II infected Indians.
Five million PBMCs were placed in a 50-ml tissue culture flask (Falcon, Becton Dickinson and Co., Franklin Lakes, NJ) containing 5 ml of RPMI 1640 (Gibco BRL Inc., Gaithersburg, MD) supplemented with 20% heat-inactivated fetal bovine serum (FBS) (Gibco BRL) and 100 U/ml penicillin and streptomycin (Gibco BRL). Cells were stimulated with 5 g/ml phytohemagglutinin (Wellcome Beckenham, UK) for 3 days. The cells were then cultivated in RPMI 1640 containing 15% FBS, 100 U/ml penicillin and streptomycin, and 50 U/ml recombinant human interleukin 2 (rhIL-2), which was kindly donated by Dr. Craig Reynolds of the Biological Response Modifiers Program of the National Cancer Institute (Frederick, MD). The medium was changed each third or fourth day, and the cell density was maintained below 1 ϫ 10 6 /ml.
HTLV antigen production
HTLV virus production in the culture supernatants was determined by using a p19 antigen capture assay (Cellular Products Inc., Buffalo, NY) according to the manufacturer's instructions (Papsidero et al., 1990) . Indirect immunofluorescence was also used to detect viral antigens in cultured cells, as previously described (Gallo et al., 1991) . Briefly, 5 l of a cell suspension (3 ϫ 10 6 cells/ml) was dried at room temperature on each well of 10-well HTC blue slides (Celline Associates Inc., Newfield, NJ). The slides were placed in acetone for 10 min. Fixed cells were incubated at 37°C for 20 min with a strong HTLV-II-positive serum diluted 1:10 in PBS. After the cells were washed with PBS, bound antibody was detected by incubation at 37°C for 20 min with goat anti-human immunoglobulin (FAB fraction) conjugated fluorescein isothiocyanate (Cappel Research Products, Durham, NC) and fluorescence was scored in a Zeiss microscope. Controls included HTLV-I (MT2) and HTLV-II (clone 19) infected cell lines, as well as an uninfected T-cell culture (H9).
Flow cytometry
The two-color flow cytometry analysis of cultured cells was performed in a Epics Profile II (Coulter Electronics, Miami, FL) flow cytometer. Cultured cells were treated with fluorochrome conjugated murine monoclonal antibodies to the CD3, CD4, CD8, CD11a, CD45RA, CD45RO, CD25, and HLA DR antigens (Coulter MaAb, Hialeah, FL, and Becton Dickinson MaAb, San Jose, CA).
Nucleic acid studies
DNA was organically extracted from fresh or cultured G2 cells and amplified via PCR, as previously described . One microgram of each DNA sample was amplified with one of the overlapping HTLV-II primer sets shown in Fig. 2 . The amplified products were detected by Southern blot hybridization using 32 P-labeled oligonucleotide probes located between the flanking primers. Amplified specific products were cloned into a TA cloning vector (Invitrogen, San Diego, CA) and sequenced using an automated sequencer (Applied Biosystems, Foster City, CA). Several clones were sequenced for each primer pair and sequences were obtained for both strands of DNA. The overlapping sequences were used to obtain the G2-specific regions homologous to the primers and to double-check the accuracy of sequences. Sequences were aligned (Needleman and Wunsch, 1970) and the neighbor-joining method utilizing the maximum likelihood technique to determine distance matrices (Felsenstein, 1989 ) was used to compare new and previously published retroviral sequences. Both distance and bootstrap (100 replications) trees were generated. The G2 cell line was analyzed for T-cell ␤-gene receptor rearrangements using a PCR assay as previously described . 
